Rosuvastatin Calcium

Statin pharmacologically acts by inhibiting cholesterol synthesis.

Excretion into breast milk is non-significant. Its low oral biodisponibility makes absorption by the infant unlikely.

Influence on alteration of breast milk fat composition is unknown. High amount of cholesterol is required by the infant to ensure appropriate development of nervous system, cell membranes and hormones or vitamin production.

Avoiding use while exclusive breastfeeding would be advisable. Atorvastatin is probably safer because of a higher molecular weight that would interfer with excretion into breast milk. Pravastatin has also shown a low excretion. Simvastatin has the lowest oral biodisponibility.

Interruption of drug hypercholesterolemia treatment while breastfeeding would probably not affect long-term outcome of the disease. A hypolipidemic diet should be followed.

Alternatives

• Atorvastatin Calcium (High Risk probable)
• Pravastatin (High Risk probable)
• Colesevelam Hydrochloride (Very Low Risk)
• Simvastatin (High Risk probable)
• Ezetimibe (Low Risk probable)
• Colestipol (Very Low Risk)
• Colestyramine (Very Low Risk)